Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review

BACKGROUND: Memantine is licensed for moderate-to-severe Alzheimer's disease (AD). National Institute for Clinical Excellence (NICE) guidance does not recommend the use of memantine in combination with cholinesterase inhibitors (acetylcholinesterase inhibitor (AChEI)). The underpinning meta-ana...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Farrimond, Lucy E, Roberts, Emmert, McShane, Rupert
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BMJ Group 2012
Pynciau:
Neurology
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3378937/
https://ncbi.nlm.nih.gov/pubmed/22689908
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2012-000917
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg